HomeCompareBSEFY vs JNJ

BSEFY vs JNJ: Dividend Comparison 2026

BSEFY yields 2.72% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $8.9K in total portfolio value· pulled ahead in Year 7
10 years
BSEFY
BSEFY
● Live price
2.72%
Share price
$15.10
Annual div
$0.41
5Y div CAGR
-17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$44.14
Full BSEFY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — BSEFY vs JNJ

📍 JNJ pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBSEFYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BSEFY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BSEFY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BSEFY
Annual income on $10K today (after 15% tax)
$230.79/yr
After 10yr DRIP, annual income (after tax)
$37.52/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,948.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BSEFY + JNJ for your $10,000?

BSEFY: 50%JNJ: 50%
100% JNJ50/50100% BSEFY
Portfolio after 10yr
$25.8K
Annual income
$2,366.77/yr
Blended yield
9.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

BSEFY
No analyst data
Altman Z
1.5
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BSEFY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBSEFYJNJ
Forward yield2.72%2.13%
Annual dividend / share$0.41$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-17.3%28%
Portfolio after 10y$21.4K$30.3K
Annual income after 10y$44.14$4,689.40
Total dividends collected$1.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BSEFY vs JNJ ($10,000, DRIP)

YearBSEFY PortfolioBSEFY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,925$224.55$10,592$272.30+$333.00BSEFY
2$11,879$189.60$11,289$357.73+$590.00BSEFY
3$12,870$159.34$12,123$472.89+$747.00BSEFY
4$13,904$133.43$13,141$629.86+$763.00BSEFY
5$14,989$111.41$14,408$846.81+$581.00BSEFY
6$16,131$92.83$16,021$1,151.60+$110.00BSEFY
7← crossover$17,337$77.21$18,122$1,588.22$785.00JNJ
8$18,615$64.14$20,930$2,228.20$2.3KJNJ
9$19,971$53.23$24,792$3,191.91$4.8KJNJ
10$21,413$44.14$30,274$4,689.40$8.9KJNJ

BSEFY vs JNJ: Complete Analysis 2026

BSEFYStock

Benesse Holdings, Inc. provides educational, senior nursing care, and childcare services in Japan and internationally. The company operates through four segments: Domestic Education, Global Kodomo Challenge, Nursing Care and Childcare, and Berlitz. The Domestic Education segment engages in the correspondence course business, school and teacher support business, cram and prep school business, English language classes for children business, and other businesses for primary school students to high school students. The Global Kodomo Challenge segment is involved in the correspondence course business in Japan, China, Taiwan, and Indonesia, primarily targeting infants. The Nursing Care and Childcare segment engages in the residential care services business, which include the operation of nursing homes and elderly homes; home helper services business; training courses for nursing care personnel; a staff placement and personnel dispatch company specializing in medical and nursing care personnel; the daycare and afterschool childcare operations business; and other businesses. The Berlitz segment is involved in the language instruction business; the ELS business, which provides educational services, including language training to those who want to study abroad; the worldwide leadership training business; and other businesses. It also offers interpretation and translation services; information and products relating to pregnancy, childbirth, and parenting; lifestyle information and support everyday living through forums for communication with customers; and magazines, websites, and others to help enrich life with pets. The company was formerly known as Benesse Corporation and changed its name to Benesse Holdings, Inc. in 2009. Benesse Holdings, Inc. was founded in 1955 and is headquartered in Okayama, Japan.

Full BSEFY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this BSEFY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BSEFY vs SCHDBSEFY vs JEPIBSEFY vs OBSEFY vs KOBSEFY vs MAINBSEFY vs ABBVBSEFY vs MRKBSEFY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.